Impact of tranexamic acid on postoperative complications and bleeding in facial aesthetic surgery: A systematic review and meta-analysis.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2025 Vol.106() p. 265-275

Prabhughate A, Bellani D, Shome D, Kapoor R, Parkar S, Shahare R

관련 도메인

Abstract

[BACKGROUND] Tranexamic acid (TXA) is a synthetic antifibrinolytic agent originally developed for hemostasis, which is now widely used in aesthetic and reconstructive surgery. Its application in facial cosmetic procedures is aimed at reducing bleeding, swelling, and bruising. This systematic review assesses the impact of TXA on postoperative outcomes in facial cosmetic surgery, focusing on blood loss, surgical time, edema, and ecchymosis.

[METHODS] This review followed the preferred reporting items for systematic reviews and meta-analyses guidelines and synthesized data from randomized controlled trials, cohort studies, and case-control studies published between 2004 and 2024. Eligible studies examined TXA in aesthetic facial surgeries (e.g., rhinoplasty, rhytidectomy, and blepharoplasty). Outcomes included intraoperative bleeding, surgical time, postoperative edema, ecchymosis, and patient satisfaction. A comprehensive search was conducted across the PubMed, Embase, Cochrane Library, and Google Scholar databases.

[RESULTS] Twenty-two studies involving 9005 patients were included. TXA significantly reduced blood loss, postoperative edema, and ecchymosis. The average surgical time was 122.17 (SD: 34.44) min, with mean blood loss of 86.63 (SD: 56.93) cc. TXA use consistently decreased drain output and postoperative complications, particularly in rhinoplasty and rhytidectomy. Various administration routes (intravenous, topical, or local infiltration) showed no significant systemic complications. Combining TXA with local anesthetics improved hemostatic and anesthetic efficacy.

[CONCLUSION] TXA is an effective adjunct in facial cosmetic surgery that reduces intraoperative bleeding, surgical time, and postoperative sequelae such as edema and ecchymosis. Further studies are needed to establish standardized dosing and objective outcome grading. TXA demonstrated safety and efficacy indicating that it should become a standard practice in facial aesthetic procedures.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
약물 txa 트라넥삼산 dict 8
시술 rhinoplasty 코성형술 dict 2
시술 rhytidectomy 안면거상술 dict 2
약물 tranexamic acid 트라넥삼산 dict 2
시술 blepharoplasty 안검성형술 dict 1
해부 blood scispacy 1
해부 intravenous scispacy 1
합병증 edema scispacy 1
약물 86.63 scispacy 1
약물 [BACKGROUND] Tranexamic acid scispacy 1
질환 bleeding C0019080
Hemorrhage
scispacy 1
질환 swelling C0013604
Edema
scispacy 1
질환 bruising C0009938
Contusions
scispacy 1
질환 blood loss C0019080
Hemorrhage
scispacy 1
질환 edema C0013604
Edema
scispacy 1
질환 ecchymosis C0013491
Ecchymosis
scispacy 1
질환 intraoperative bleeding scispacy 1
질환 postoperative edema scispacy 1
질환 postoperative sequelae scispacy 1
기타 patient scispacy 1
기타 patients scispacy 1

MeSH Terms

Humans; Tranexamic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; Postoperative Hemorrhage; Postoperative Complications; Ecchymosis; Edema; Face; Rhytidoplasty; Rhinoplasty; Operative Time

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문